+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers



Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers



American Journal of Cancer Research 1(6): 787-805



A tumor represents a complex structure containing malignant cells strictly coupled with a large variety of surrounding cells constituting the tumor stroma (TS). In recent years, the importance of TS for cancer initiation, development, local invasion and metastases has become increasingly clear allowing the identification of TS as one of the possible ways to indirectly target tumors. Inside the heterogeneous stromal cell population, tumor associated fibroblasts (TAF) play a crucial role providing both functional and supportive environments. During both tumor and stroma development, several findings suggest that TAF could be recruited from different sources such as locally derived host fibroblasts, via epithelial/endothelial mesenchymal transitions or from circulating pools of fibroblasts deriving form mesenchymal progenitors, namely mesenchymal stem/stromal cells (MSC). These insights prompted scientists to identify multimodal approaches to target TS by biomolecules, monoclonal antibodies, and more recently via cell based strategies. These latter strategies appear extremely promising, although still associated with debated and unclear findings. This review discusses crosstalk between cancers and their stroma, dissecting specific tumor types, such as sarcoma, pancreatic and breast carcinoma, where stroma plays distinct paradigmatic roles. The recognition of these distinct stromal functions may help in planning effective and safer approaches aimed either to eradicate or to substitute TS by novel compounds and/or MSC having specific killing activities.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 056754908

Download citation: RISBibTeXText

PMID: 22016827


Related references

Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Journal of the National Cancer Institute 96(21): 1593-1603, 2004

Re: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Journal of the National Cancer Institute 97(7): 540-1; Author Reply 541-2, 2005

The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handbook of Experimental Pharmacology 2007(180): 263-283, 2007

Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. Molecular Imaging and Biology 13(6): 1234-1240, 2012

Fludarabine is toxic for bone marrow (BM) mesenchymal (MP) and hematopoietic progenitors (HP) and alters the adhesion of hematopoietic progenitors to BM stroma suggesting its direct effect on HP mobilization'. 2007

Dual energy CT for monitoring targeted therapies in patients with advanced gastrointestinal stromal tumor: initial results. Current Pharmaceutical Biotechnology 12(4): 547-557, 2011

Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene. Journal of Nuclear Medicine 56(4): 600-606, 2015

Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacology and Therapeutics 157: 120-124, 2016

Non-multipotent stroma inhibit the proliferation and differentiation of mesenchymal stromal cells in vitro. CytoTherapy 12(6): 818-830, 2011

Isolation and characterization of mesenchymal stromal progenitors from the temporomandibular joint disc. Journal of Tissue Engineering and Regenerative Medicine 11(5): 1553-1561, 2015

Non-adherent mesenchymal progenitors from adipose tissue stromal vascular fraction. Tissue Engineering. Part a 20(5-6): 1081-1088, 2014

The place of targeted therapies in the management of non-small cell bronchial carcinoma. Biological mechanisms of bronchial carcinogenesis: towards a better understanding and the development of new therapies. Revue des Maladies Respiratoires 23(5 Pt 3): 16s123-16s130, 2007

Targeted therapies in gastrointestinal stromal tumors. Seminars in Diagnostic Pathology 25(4): 295-303, 2008

The exciting prospects of new therapies with mesenchymal stromal cells. CytoTherapy 19(1): 1-8, 2016